STOCK TITAN

Day One to Present at the 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Day One Biopharmaceuticals (Nasdaq: DAWN) announced that CEO Dr. Jeremy Bender will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9 at 4:30 p.m. PT / 7:30 p.m. ET. A live audio webcast will be accessible on the Company's website, with a replay available for 30 days post-event.

Day One focuses on developing targeted therapies for pediatric cancer, addressing unmet medical needs. Their lead candidate, tovorafenib (DAY101), is a selective pan-RAF kinase inhibitor, complemented by pimasertib, a MEK-1/-2 inhibitor.

Positive
  • None.
Negative
  • None.

SOUTH SAN FRANCISCO, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Dr. Jeremy Bender, chief executive officer, will present during the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9 at 4:30 p.m. Pacific Time / 7:30 p.m. Eastern Time.

A live audio webcast of the presentation will be available by visiting the Events & Presentations section of the Company’s website at www.dayonebio.com. An archived replay of the webcast will be available for 30 days following the live presentation.

About Day One Biopharmaceuticals
Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company that believes when it comes to pediatric cancer, we can do better. We put kids first and are developing targeted therapies that deliver to their needs. Day One was founded to address a critical unmet need: the dire lack of therapeutic development in pediatric cancer. The Company’s name was inspired by “The Day One Talk” that physicians have with patients and their families about an initial cancer diagnosis and treatment plan. Day One aims to re-envision cancer drug development and redefine what’s possible for all people living with cancer—regardless of age—starting from Day One.

Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important emerging cancer treatments. The Company’s lead product candidate, tovorafenib (DAY101), is an investigational, oral, brain-penetrant, highly-selective type II pan-RAF kinase inhibitor. The Company’s pipeline also includes pimasertib, an investigational, oral, highly-selective small molecule inhibitor of mitogen‐activated protein kinases 1 and 2 (MEK-1/-2). Day One is based in South San Francisco. For more information, please visit www.dayonebio.com or find the company on LinkedIn or Twitter.

DAY ONE MEDIA
Laura Cooper, Head of Communications
laura.cooper@dayonebio.com

DAY ONE INVESTORS
Hans Vitzthum, LifeSci Advisors
hans@lifesciadvisors.com


FAQ

When will Day One Biopharmaceuticals present at the J.P. Morgan Healthcare Conference?

Day One Biopharmaceuticals will present on January 9 at 4:30 p.m. Pacific Time / 7:30 p.m. Eastern Time.

How can I listen to the Day One Biopharmaceuticals presentation?

The presentation will be available via a live audio webcast on the Company's website.

What is the focus of Day One Biopharmaceuticals?

Day One Biopharmaceuticals is dedicated to developing targeted therapies for pediatric cancer.

What is tovorafenib and its relevance to Day One Biopharmaceuticals?

Tovorafenib (DAY101) is Day One's lead product candidate, a selective pan-RAF kinase inhibitor being developed for cancer treatment.

What other products are in the pipeline of Day One Biopharmaceuticals?

In addition to tovorafenib, Day One's pipeline includes pimasertib, a small molecule inhibitor of MEK-1/-2.

Day One Biopharmaceuticals, Inc.

NASDAQ:DAWN

DAWN Rankings

DAWN Latest News

DAWN Stock Data

1.50B
100.85M
17.49%
77.81%
16.25%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BRISBANE